● SK bioscience selects underwriters for IPO
- NH Investment & Securities selected as the lead underwriter and Korea Investment & Securities as the co-underwriter
- Listing targeted for next year to expand business and accelerate growth by securing new investment
SK bioscience selected NH Investment & Securities as the lead underwriter and Korea Investment & Securities as its co-underwriter to manage its initial public offering (IPO) during 2021.
The company explained that the purpose of going public was to expand its business and accelerate further growth by securing new investment.
SK bioscience has developed SKYCellflu Quadrivalent, the world＇s first cell culture-based quadrivalent flu vaccine, SKY Zoster, the world＇s second herpes zoster vaccine, and SKY Varicella, the second varicella vaccine developed in Korea. New products currently being developed include a COVID-19 vaccine and next-generation pneumococcal vaccine.
SK bioscience has been aggressively entering overseas markets and expanding its business portfolio and recently signed a CMO contract with AstraZeneca, a global pharmaceutical company, to supply COVID 19 vaccines.
A company official said, "The IPO will be conducted under conditions that allow us to be valued properly.”
SK bioscience is a vaccine company that was spun off from SK chemicals in July 2018.